April 7, 2020
UC San Diego Health Statement Regarding Hydroxychloroquine
As soon as rumors began to circulate about hydroxychloroquine’s unproven potential to treat patients with COVID-19, UC San Diego Health pharmacies sequestered their available medication supply and implemented a plan to conserve supplies to be dispensed only for existing patients with lupus, rheumatoid arthritis and other approved indications. Hydroxychloroquine is FDA-approved for the treatment of only those few conditions. Insufficient information regarding hydroxychloroquine efficacy in COVID-19 infection is available to recommend its use in the absence of clinical trials data. UC San Diego Health does not support the use of medications in ways for which there is not yet scientific evidence to support safety and efficacy.
Since UC San Diego Health leaders sought out expert opinion from their faculty early in the emergency, and moved quickly to implement this plan before hydroxychloroquine supplies were exhausted, we are confident our patients who rely on hydroxychloroquine will be able to continue refilling their prescriptions without issue.
At the same time, UC San Diego Health experts are interested in assessing hydroxychloroquine’s potential to treat COVID-19 in a safe, scientific manner. To do that, our researchers are completing the necessary steps to participate in existing clinical trials and launch our own investigations of the medication.
COVID-19 information for UC San Diego Health patients and visitors.